Estrogen signaling drives breast cancers but reduces colorectal cancer incidence. Accumulating evidence support that activation of ERbeta (ESR2) can prevent colon cancer development, and this receptor is thus a potential target for receptor-selective preventive therapy. Data support regulation of tumor suppressors and oncogenes, anti-inflammatory activity and impact on microbiota. However, the underlying mechanism is not fully understood.